WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings

Simply Wall St.03-24

WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621006791?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-03-24 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621006791","market":"hk","top_or_hot":-1,"title":"WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings","media":"Simply Wall St.","content":"<div>\n<p>WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 18:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na","article_id":"2621006791","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621006791","pubTimestamp":1774346629,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago.\nSee...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","02268":"药明合联","BK4112":"金融交易所和数据","BLSG":"2倍做多BLSH ETF-Leverage Shares","BLSX":"Tradr 2X Long BLSH Daily ETF"},"translate_title":"WuXi XDC Cayman(SEHK：2268)利润率下滑测试2025财年盈利后看涨增长叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSG":0.6,"02268":1.96,"BLSX":0.6},"content_text":"WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago. See our full analysis for WuXi XDC Cayman. With the latest earnings on the table, the next step is to set these numbers against the prevailing narratives around WuXi XDC Cayman and see which stories hold up and which need to be reconsidered. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2268 Revenue & Expenses Breakdown as at Mar 2026 AdvertisementTTM revenue at C¥5.9b with earnings growth running at 38.4%  Over the last twelve months, WuXi XDC Cayman reported total revenue of C¥5.9b and net income of C¥1.5b, with earnings growth over the past year of 38.4% compared with a 53.6% per year average over five years. What stands out for the bullish view that WuXi XDC is an ADC and bioconjugate specialist is how these growth rates line up with the story of a high demand platform:\n     Revenue over the trailing twelve months of C¥5.9b compares with C¥4.1b a year earlier, which heavily supports the bullish idea that the service model has been scaling. Earnings growing 38.4% over the last year, while slower than the 53.6% five year pace, still fits a bullish narrative that growth remains strong even as the company becomes larger.    On these numbers, many bulls would say the core ADC infrastructure story is playing out in the financials, even if growth is not matching the earlier five year pace. 🐂 WuXi XDC Cayman Bull Case Net margin at 24.9% versus 26.4% a year ago  The trailing net margin sits at 24.9%, compared with 26.4% a year earlier, alongside half year net income of C¥745.7m in 2025 H1 and C¥734.8m in 2025 H2. Critics who focus on risks around margins and concentration can point to this small margin decline as a point to watch, even alongside high earnings quality:\n     The move from a 26.4% net margin to 24.9% suggests profitability per unit of revenue is slightly lower, which gives bearish voices a concrete data point when they question how margins will hold in a more mature phase. At the same time, earnings quality being described as high means bears need to square their concerns with the fact that current profits are not being flattered by obvious one offs or low quality items.    Skeptical investors may treat the margin slip as a stress test for the business model rather than a sign of any immediate breakdown. 🐻 WuXi XDC Cayman Bear Case P/E of 42x and DCF fair value at HK$139.55  The shares trade on a trailing P/E of 42x at a price of HK$56.15, a little below the peer average of 43.1x and above the Asian Life Sciences industry average of 30.7x, while a DCF fair value of HK$139.55 and an analyst price target of HK$85.25 both sit above the current price. What is interesting for investors weighing upside potential is how the different valuation signposts line up against the growth profile:\n     Forecast earnings growth of about 27.25% per year and revenue growth of 25% per year, versus 8.2% for the Hong Kong market, are the kind of figures investors often associate with higher P/E multiples than the market average. The gap between the HK$56.15 share price, the HK$85.25 analyst target and the HK$139.55 DCF fair value creates a spread of views that investors can compare with the current 24.9% margin and growth rates when deciding how much of that potential to factor into their own expectations.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on WuXi XDC Cayman's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. With the mix of bullish and cautious signals in mind, take a moment to look through the figures yourself and decide how they stack up for your portfolio. To see why some investors are focusing on the positive side of the story, check out the 4 key rewards. See What Else Is Out There WuXi XDC Cayman carries a relatively high 42x P/E with slightly lower net margins than a year ago, which may give valuation conscious investors pause. If that mix of rich pricing and margin pressure feels tight for your comfort, compare it with companies in the 244 high quality undervalued stocks to see where the numbers may look more forgiving.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi XDC Cayman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621006791","isCrawlerRequest":true}